---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-047220"
form_type: "8-K"
ticker: "JAGX"
cik: "0001585608"
company_name: "Jaguar Health, Inc."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T01:48:51.908919+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Jaguar Health 2024 revenue $11.7M, up 20% YoY; net loss narrows to $38.5M

## Summary
- 2024 net revenue of ~$11.7M (prescription+non-prescription+license) increased ~20% from $9.8M in 2023.
- Q4 2024 revenue of ~$3.5M rose 13% sequentially and 53% YoY; Mytesi prescription volume up 3.9% in 2024.
- Net loss attributable to common shareholders improved to $38.5M from $41.3M in 2023; R&D spend fell $2.1M to $16.5M.
- Expects first proof-of-concept results in Q2 2025 for crofelemer in short bowel syndrome and microvillus inclusion disease trials.
- FDA meeting scheduled Q2 2025 to discuss Phase 3 OnTarget trial results in breast cancer subgroup.

## SEC filing metadata
- accession: 0000950170-25-047220
- form_type: 8-K
- ticker: JAGX
- cik: 0001585608
- company_name: Jaguar Health, Inc.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1585608/000095017025047220/0000950170-25-047220-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1585608/000095017025047220/jagx-20250331.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-047220
- JSON: https://secwatch.observer/filing/0000950170-25-047220.json
- Plain text: https://secwatch.observer/filing/0000950170-25-047220.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.